BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

  • Jefferies Global Healthcare Conference in New York on Wednesday, June 4, 2025, at 4:55 p.m. ET.



  • Goldman Sachs 46th Annual Global Healthcare Conference in Miami on Monday, June 9, 2025, at 8:40 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on .

BCRXW

Contact:

John Bluth





EN
27/05/2025

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Reports Full Year 2025 Financial Results and Provides Busines...

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update —Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)— —Record GAAP and non-GAAP operating profit for full year 2025— —Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million— —Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to

8h / 19m 1 EN
Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NFLX NETFLIX INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
RVMD INC.
OCUP REVOLUTION MEDICINES
DAWN OCUPHIRE PHARMA INC
STX DAY ONE BIOPHARMACEUTICALS INC
GLUE SEAGATE TECHNOLOGY HLDGS PLC
GFS MONTE ROSA THERAPEUTICS INC
MLTX GLOBALFOUNDRIES INC
EWTX MOONLAKE IMMUNOTHERAPEUTICS
QBTS EDGEWISE THERAPEUTICS INC
IONQ D-WAVE QUANTUM INC.
DBD IONQ INC
BCAX DIEBOLD NIXDORF INCORPORATED
BICARA THERAPEUTICS INC.
02/23/26 February 23, 2026 1 EN
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
SRPT Sarepta Therape...
NVCR NOVOCURE LTD. ... (+20)

The Week Ahead in Life Sciences

Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent

SRPT SAREPTA THERAPEUTICS INC.
NVCR NOVOCURE LTD.
MNKD MANNKIND CORP.
GERN GERON CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
WVE WAVE LIFE SCIENCES
UTHR UNITED THERAPEUTICS CORPORATION
NTLA INTELLIA THERAPEUTICS INC.
ARGX ARGENX ADS
APLS APELLIS PHARMACEUTICALS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
OCUP OCUPHIRE PHARMA INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
GLUE MONTE ROSA THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
02/23/26 February 23, 2026 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Present at Upcoming Investor Conference

BioCryst to Present at Upcoming Investor Conference RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026, at 9:10 a.m. ET. The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at . About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) an...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Nav...

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia from February 27-March 2, 2026. Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralsta...

February 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch